clinical trial · NCT06607549
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
Central Nervous System LymphomaLoncastuximab tesirine and rituximab (Lonca-R)
brief summary
The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.
started
Mar 18, 2025
primary completion
Nov 1, 2029
completion
Nov 1, 2030
last updated
Dec 3, 2025
official title
A Phase 1 Study of Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery (SRS) in Patients With Primary and Secondary Central Nervous System Lymphomas
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol